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Key Points 
- Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery 
- This study aims to establish a population pharmacokinetic (PK) model describing the perioperative 
FIX levels 
- Population PK parameter values for CL and V1 were 284 mLh
-1
70kg
-1
 and 5450 mL70kg
-1
, 
respectively 
- Perioperative PK parameter estimates are significantly different from the non-surgical prophylactic 
treatment 
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Abstract 
 
Background 
Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the 
perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually 
dosed according to body weight, under- and overdosing occurs frequently during surgery. 
 
Aim 
The objective was to quantify and explain the inter-patient variability of perioperatively administered 
plasma-derived (pd) and recombinant (r) FIX concentrates. 
 
Methods 
Data were collected from 118 patients (median age: 40 years (range: 0.2-90), weight: 79 kg (range: 
5.3-132)) with moderate (28%) or severe hemophilia B (72%), undergoing 255 surgical procedures. 
Population pharmacokinetic (PK) parameters were estimated using nonlinear mixed-effect modeling in 
NONMEM. 
 
Results 
Measured perioperative FIX level versus time profiles were adequately described using a three-
compartment PK model. For a typical 34-year-old patient receiving rFIX, clearance (CL), inter-
compartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral 
compartments (V2, V3) plus inter-patient variability (%CV) were: CL: 284 mLh
-1
70kg
-1
 (18%), V1: 5450 
mL70kg
-1
 (19%), Q2: 110 mLh
-1
70kg
-1
, V2: 4800 mL70kg
-1
, Q3: 1610 mLh
-1
70kg
-1
 and V3: 2040 
mL70kg
-1
. From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the 
age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients 
receiving rFIX. Inter-patient variability was successfully quantified and explained. 
 
Conclusions 
The estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported 
for prophylactic treatment. The developed model may be used to apply PK-guided dosing of FIX 
concentrates during surgery. 
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Keywords: Hemophilia B, Coagulation Factor IX, Surgery, Pharmacokinetics, Coagulation Factor 
Concentrates. 
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Introduction 
Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). 
Severe and moderate patients have endogenous FIX levels less than 0.01 IUmL
-1
 and between 0.01 
and 0.05 IUmL
-1
, respectively [1,2]. In this category of patients, plasma-derived FIX (pdFIX) or 
recombinant FIX (rFIX) standard half-life concentrates are usually administered prophylactically to 
prevent spontaneous joint and muscle bleedings [3,4] and ‘on-demand’ when bleeding occurs in the 
surgical setting. In the prophylactic setting, FIX trough levels above 0.01 IUmL
-1
 are usually aimed for, 
as moderate patients have significantly less spontaneous bleedings [5]. In the perioperative setting, 
higher doses of FIX concentrates are administered to normalize FIX levels for 7-10 consecutive days 
post-surgery with target trough levels from 1.00 to 0.30 IUmL
-1
 ensuring adequate hemostasis [6]. 
Currently, prophylactic, “on-demand” and perioperative dosing of FIX concentrates is performed 
according to body weight with frequent monitoring to ensure sufficient FIX levels. Despite weight-
based dosing, considerable under- and overdosing in the surgical setting has been reported by 
Hazendonk et al [7]. It was shown that 60% of the hemophilia B patients have FIX levels below the 
target level range during the first 24 hours directly after surgery. This lack of adequate FIX plasma 
levels confers a considerable potential risk of bleeding and should be avoided. Therefore, more 
optimal dosing strategies are warranted. 
In the prophylactic setting, FIX doses can be tailored to an individual’s need by pharmacokinetic (PK)-
guided dosing using Bayesian analysis [8]. In this approach, observed individual FIX levels are 
combined with PK information assessed in the population in order to obtain estimates for individual PK 
parameters [9]. These individual parameter estimates can be used to calculate doses necessary to 
achieve and maintain desired target levels by PK-guided dosing, potentially preventing over and 
under-dosing. This approach can be applied iteratively, as with every new blood sample the calculated 
dose can be adapted to alterations in the individual PK parameter estimates [10]. This technique may 
also be applied in the perioperative setting. 
A prerequisite for applying Bayesian analysis to perioperative dosing of FIX is the availability of a 
population model that describes the PK of FIX in hemophilia B patients undergoing surgery. The 
population PK of pdFIX and rFIX is well documented [5,11–13]. However, these models have all been 
constructed using data during non-surgical dosing of FIX concentrates. In the perioperative setting, the 
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PK of FIX may however be altered. In order to apply Bayesian dosing in the perioperative setting, a 
dedicated population model should be available. 
This study was performed to describe the population PK of pdFIX and rFIX concentrates in hemophilia 
B patients during surgery and the days thereafter. It was investigated whether specific patient and 
surgical characteristics explain inter-patient variability (IIV) in FIX exposure and whether the 
perioperative PK of FIX is comparable to the prophylactic situation. 
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Methods 
 
Patients and clinical data 
An international multi-center observational cohort study was performed in which data were collected 
from 118 severe and moderate hemophilia B patients from five Hemophilia Treatment Centers in the 
Netherlands and five in the United Kingdom. Patients of all ages, who had undergone a minor or major 
elective surgical procedure between January 1
st
 2000 and December 1
st
 2015, were included [14]. 
Details of the study data have been reported previously [7]. 
In summary, severe and moderate hemophilia B patients received replacement therapy during surgery 
with FIX concentrates according to national and/or hospital guidelines, while aiming for target FIX 
levels as prescribed. To ensure hemostasis during the surgical procedure, a pdFIX product 
[AlphaNine
®
 SD (Grifols Biologicals Inc., Los Angeles, USA), Replenine
®
 (Bio Products Laboratory, 
Hertfordshire, UK), Haemonine
®
 (Biotest Pharma GmbH, Dreierich, Germany), Mononine
®
 (CSL 
Behring GmbH, Marbourg, Germany) and Nonafact
®
 (Sanquin, Amsterdam, the Netherlands)] or rFIX 
product [BeneFix
®
 (Pfizer Wyeth Pharmaceuticals Inc., Kent, UK) and IXinity
®
 (Aptevo 
BioTherapeutics LLC, Berwyn, US)] was administered with a bolus infusion of approximately 100 IUkg
-
1
, followed by either multiple intermittent bolus infusions or continuous infusions. FIX levels were 
obtained in the participating centers using a one-stage assay, according to local protocol. 
 
Pharmacokinetic modeling 
In population PK modeling, the PK is assessed in a cohort of patients rather than in an individual 
patient [15]. In population PK modeling, not only the average or median value of a PK parameter is of 
interest but also its inter- and intra-patient variability. Population PK parameters can be obtained by 
the standard two-stage method, in which individual PK parameters are calculated and, subsequently, 
summarized. A drawback of this method is that for each individual 10 or more serial samples should 
be available (rich sampling). In the clinical situation, this is often impossible or inconvenient to perform, 
especially in populations such as children or the elderly. An alternative is the population approach [16], 
which allows the estimation of population PK parameters by analyzing data from all the patients 
simultaneously. The simultaneous analysis allows the use of sparsely and heterogeneously sampled 
8 
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data, which is frequently encountered in the clinical situation. In this study, sparsely and 
heterogeneously sampled data were used to construct the population PK model. 
Using the population-based approach, a structural PK model is established first. This model consists 
of a number of PK compartments with PK parameters described in terms of clearance and volume of 
distribution. The structural model provides values for the typical (average) parameter and, importantly, 
several levels of variability. Differences in PK parameters between patients are quantified in terms of 
inter-patient variability (IIV). Variability of a PK parameter within a patient may be quantified by 
estimation of inter-occasion variability (IOV). Furthermore, a population PK model contains residual 
unexplained variability (RUV), which is the variability of the differences between the predicted and the 
measured plasma levels. By combining observed individual FIX levels and population PK parameters 
empirical Bayesian estimates (EBEs) of the individual PK parameters can be obtained. These EBEs 
can be used in the covariate analysis (below). 
In this study, nonlinear mixed-effects modeling was used to estimate the population PK parameters 
[17]. A detailed description of the methods used to construct the population PK model can be found in 
the Supplemental data. For each patient, the (historically lowest) endogenous baseline level was 
subtracted from each observed FIX level. Furthermore, in some subjects, a preoperative FIX level was 
present that was higher than the measured endogenous baseline level and for which no prior dose 
information was known. In the modeling procedure, the pre-operative level was accounted for by an 
arbitrary virtual dose of 8250 IU administered 5 days prior to the pre-dose FIX measurement. To 
account for inter- and intra-individual variability in the observed preoperative FIX levels, the typical 
bioavailability of this dose was estimated in combination with its IIV and IOV. For estimation of the 
IOV, an occasion was defined as a single surgical procedure. 
After the structural model was established, it was evaluated whether patient and surgical 
characteristics (covariates) explained the variability (IIV, IOV, and RUV) in a covariate model. Since 
FIX levels were available for both children and adults, estimated PK parameters were normalized for a 
body weight of 70 kg using allometric scaling with the ¾ rule [18]. Body weight was, however, missing 
in 38 surgical procedures (14.9%) from 18 patients (15.3%). Therefore, a piecewise linear model was 
developed to impute the missing values for body weight using age as a predictor. Covariate 
relationships were evaluated using graphical evaluation of plots of the EBEs versus the covariate 
value. Subsequently, covariates were implemented in the population model and their ability to explain 
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the IIV, IOV or RUV was tested by univariate analysis. The following covariates were evaluated: 
severity of hemophilia (severe versus moderate), age, the use of tranexamic acid or heparin during 
surgery, the type of FIX concentrate (plasma-derived or recombinant), the brand of product, treatment 
center, country of treatment, presence of hepatitis C, the use of prophylaxis before the surgical 
procedure, a history of neutralizing inhibitors, having a minor or major surgical procedure, blood group 
and the presence of an infection or a decrease in hemoglobin concentration during the surgical 
procedure. The final model, containing multiple covariates, was constructed by multivariate analysis 
using forward inclusion and backward deletion. 
 
Model evaluation 
The objective function value (OFV), which represents the ability of the model to describe the observed 
FIX levels, was used to discriminate between different models. When comparing nested models, the 
difference of the corresponding OFVs (dOFV) is known to be described by a χ
2
 distribution, in which 
the difference in the number of parameters between the evaluated models determines the degrees of 
freedom. Hereby, a dOFV bigger than 3.84, 5.99 or 7.81 indicates a significant difference of P < .05 
with 1, 2, or 3 degrees of freedom, respectively. In the covariate analysis, covariates were selected in 
the forward inclusion and backward elimination procedure if a dOFV bigger than 3.84 (P < .05, df=1) 
and 6.63 (P < .01, df=1), respectively, were obtained. 
To evaluate whether the measured FIX levels were adequately described by the developed population 
PK model, several criteria were used. The adequacy of the model was evaluated by inspection of 
precision of the estimated model parameters, creation of goodness-of-fit plots, evaluation of shrinkage 
of the IIV, IOV, and RUV, the condition number of the model and the creation of visual predictive 
checks (VPC) [19,20]. In the latter procedure, FIX levels were generated by Monte Carlo simulation 
(n=1000) using the established population PK model and are, subsequently, compared to the actual 
measured FIX levels [21]. For the goodness-of-fit plots, the measured FIX levels were compared to the 
population predicted FIX levels (PRED) using the typical values for the PK parameters and the 
individual predicted FIX levels (IPRED) predicted on basis of the EBE. Moreover, several plots were 
evaluated depicting conditional weighted residuals (CWRES). CWRES are the weighted difference 
between the model predicted and measured FIX levels [22]. 
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The stability and robustness of the final model were tested by a bootstrap analysis [23]. In this 
analysis, 1000 new datasets were created by randomly sampling from the data from all patients in the 
original dataset. Subsequently, the final model was re-estimated using the bootstrapped datasets. The 
median and 95% confidence interval of the obtained bootstrap parameters was compared to the 
estimated PK parameters of the final model. 
 
Comparison to non-surgical FIX models 
The final population model describing the PK of FIX in hemophilia B patients during surgery was 
compared to published population PK models derived from data of patients on prophylaxis [11–
13,24].To evaluate whether the published prophylactic models were able to describe the perioperative 
FIX levels from this study, predictions of the perioperative FIX levels were calculated using the 
prophylactic population PK parameters. For each model, the difference between the population 
predictions and the measured FIX levels was summarized using the relative mean prediction error 
(rMPE). The latter was calculated using the following equation: 
!"#$ =  
!
!
!!"#$!!!"#:!
!!"#:!
!
!!! ∗ 100% (Eq. 1) 
in which, Cpred are the population predictions and CFIX:C the measured FIX level for a total of n 
measurements. Furthermore, the terminal elimination half-life was calculated using the values from all 
population PK parameters. 
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Results 
 
Patients 
In total, 118 severe and moderate hemophilia B patients were included undergoing 262 surgical 
procedures. Four occasions were excluded, as FIX levels were not measured. Due to the withdrawal 
of approval for IXinity
®
 by the European Medicine Agency during data collection in June 2013, another 
three surgical procedures were also excluded from analysis [25]. As a result, data from 255 surgical 
procedures were used for PK analysis. Table 1 shows the general patient characteristics. 
Body weight was not recorded in 14.9% of all surgical procedures. Therefore, a piecewise linear model 
was developed, from which the missing values for body weight could be imputed using age 
(Supplemental methods). Table S1 shows the parameter estimates for the piecewise linear model. 
The relationship between age and body weight is shown in Figure 1; the blue line depicts the 
predictions from the model for all ages, which was used to impute values for the missing body weights. 
 
Pharmacokinetic modeling 
For constructing the structural model, a three-compartment model more adequately fitted the FIX 
levels than a two-compartment model (dOFV = 58.1, p<0.001). Table 2 summarizes the parameter 
estimates of the structural model. For all estimated PK parameters, the imprecision of the estimated 
value was lower than 20%. A proportional residual error model was most appropriate to fit the data, as 
compared to an additive or combined residual error model. In the structural model, IIV could be 
estimated for both CL and V1, as well as a correlation for the IIV between the two parameters. 
Moreover, shrinkage values for the IIV of CL and V1 were lower than 20%, indicating that there was 
sufficient information available for each patient to estimate the individual parameters reliably [26]. 
Although IIV should also be present for the other PK parameters (e.g. Q2, Q3, V2, V3), the available 
data did not support the estimation of these values. Pre-administration FIX levels (greater than 
endogenous baseline values) were present in 138 of the 255 evaluated surgical procedures and 
ranged from 0.01 to 0.67 IUmL
-1
. Administration of a virtual dose of 8250 IU, 120 hours before the start 
of the surgery, adequately approximated the pre-administration FIX levels and significantly improved 
the fit of the model; dOFV was -495.5 (P < .001). The typical value for the estimated bioavailability of 
the virtual dose was 99.8% and IIV and IOV values were 91% and 93%, respectively. These values 
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indicate that virtual doses vary largely between patients and surgical procedures with values ranging 
from 744.2 IU to 196,824.2 IU. Estimation of IOV for differences in CL and V1 between surgical 
procedures was not successful. By implementing IOV for CL, the fit of the model improved (dOFV: -
141.9, P < .01). However, parameter estimates became unstable and IOV was therefore not included. 
 
Covariate analysis 
To prevent the covariates influencing the estimation of the virtual dose, the IIV and IOV from the virtual 
dose were fixed to the values obtained for the structural model. Table 3 shows the dOFV for the 
selected covariate relations from the forward inclusion and backward elimination procedure. Age of the 
patient was included for CL and V1 as a piecewise linear model, which is a linear model with two 
slopes. The best fit was obtained when the first slope was estimated and the second was set to zero 
from an age of 34 years, which was the median, and higher. As a result, the body weight normalized 
CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Moreover, 
IIV was reduced from 20.8% to 18.5% (10.1%) and from 24.6% to 18.7% (14.6%) for CL and V1 due 
to the introduction of age. In Figure 2A-B, age versus individual values for CL and V1, as obtained by 
Bayesian analysis using the final model, are shown. In these figures, the combined effect of body 
weight and age is observed, as CL and V1 increase with body weight and decrease with age up to 34 
years. 
Patients receiving pdFIX concentrates exhibited a lower CL and V1 as compared to patients receiving 
rFIX concentrates; respective values were 11% and 17% lower for pdFIX. Moreover, V1 was 10% 
lower in patients with moderate hemophilia in comparison to patients with severe hemophilia. The 
parameters of the final model are summarized in Table 2. All other covariate relations did not result in 
a significant dOFV. 
 
Evaluation of the final model 
The fit of the final model was evaluated by inspection of goodness-of-fit plots, as shown in Figure 3A-
D. Figure 3A shows the prediction of FIX levels, based on the population PK parameter values, 
adjusted for the covariate values. Both under- and overprediction is present since IIV is not taken into 
account for calculating the population predictions. Nevertheless, the population predictions are 
distributed randomly around the y=x axis, demonstrating the appropriateness of the model. Figure 3B 
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is obtained after Bayesian analysis, in which individual PK parameter estimates (EBEs) are obtained 
by simultaneous analysis of the individual observations and the population model. The individual FIX 
levels are predicted using the derived EBEs. Again, these predictions are distributed randomly around 
the y=x axis. Figure 3C-D show plots of the conditional weighted residuals (CWRES) versus predicted 
FIX level and time, respectively. CWRES values are distributed randomly around the line y=0. Most of 
the values are within the -2 and +2 SD range, which confirms the goodness-of-fit of the final model. 
To evaluate the stability of the final model, a bootstrap analysis was performed. In this analysis, 1000 
model estimations were performed from which 98.3% were successful. Table 2 shows that the 
medians for the parameter estimates from the bootstrap analysis were similar to those from the final 
model, except for Q3. This deviation for Q3 is caused by the high imprecision of its estimation, as 
shown by the 95% CI for Q3 from the bootstrap analysis (667.2 - 5131.9 mLh
-1
70kg
-1
). For all other 
parameters of the final model, the CIs were small and corresponded to the RSEs from the parameter 
estimates of the final model. 
The evaluation of the final model comprised of 1000 Monte Carlo simulations for each patient to 
construct a VPC, as shown in Figure 4. The (grey) lines, depicting the 2.5
th
, 50
th
 and 97.5
th
 percentiles 
of the measured FIX levels, are predominantly within their corresponding 95% prediction intervals, as 
presented by blue and red areas. As a result, the simulated data were similar to the measured data, 
confirming the adequacy of the final model. 
 
Comparison with non-surgical models 
Supplementary Table S2 summarizes population PK parameters of four models that have been 
published previously and were constructed using data obtained after non-surgical dosing. Higher 
values for the population PK parameter CL were found for the rFIX models as compared to the pdFIX 
models. Supplementary Figure S2 shows the predicted FIX levels as obtained using the population PK 
parameter values analogous to Figure 3A (without IIV). Supplementary Figure S2A-B were 
constructed using solely the pdFIX data from this study; concentrations were predicted using the 
population parameters of pdFIX model 1 and 2. Likewise, Supplementary Figure S2C-D were 
constructed using solely the rFIX data from this study in combination with population parameters from 
rFIX model 1 and 2. In each case, the non-surgical models underpredicted the observed levels, as 
shown by the blue lines being above the black line y=x. The rMPE values, calculated for pdFIX model 
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1 and 2 and rFIX model 1 and 2, were -7.2%, -15.7%, -40.7% and -40.3%, respectively. Furthermore, 
the half-lives calculated for pdFIX and rFIX using the population parameter values for the final model 
from the present study were 51 and 49 hours, respectively, whereas the terminal elimination half-lives 
for pdFIX model 1 and 2 and rFIX model 1 and 2 were: 28, 23, 20 and 20.3 hours, respectively. 
15 
20180829_A perioperative population PK model for FIX 
Discussion 
In this study, the PK of pdFIX and rFIX were characterized in children and adults with severe and 
moderate hemophilia B undergoing a surgical procedure. Considerable inter-patient variability was 
identified for clearance and central volume of distribution, which was partially explained by the 
patient’s age, type of FIX product and the severity of hemophilia. Importantly, the perioperative PK of 
FIX was different from that in the non-surgical situation. 
 
In population PK analysis, the variability within and between patients is quantified and, subsequently, 
explained using covariates such as age or body weight. When these variabilities are assessed 
adequately, a population PK model may be used for PK-guided dosing using Bayesian analysis. In 
contrast to dosing based on body weight, PK-guided dosing allows for individualization of doses while 
taking the individual’s PK into account. To apply Bayesian analysis clinically, an appropriate 
population PK model is essential. Moreover, Bayesian analysis using a population PK model, which 
does not describe the PK of FIX adequately, may result in biased individual PK parameters and, 
hence, biased estimated doses. For factor VIII, a dedicated population PK model for hemophilia A 
patients undergoing a surgical procedure was constructed in a similar fashion [27]. Therefore, a 
dedicated population PK model was constructed to describe the perioperative FIX levels. 
 
In this study, the observed pre-surgical FIX level was higher than the endogenous baseline value in 
138 of 255 surgical procedures. These elevated pre-surgical FIX levels were taken into account by a 
virtual dose that was estimated using a typical value and both IIV and IOV. Hereby, each patient 
having a pre-surgical FIX level can have a different virtual dose for each surgical procedure. Inclusion 
of these pre-surgical FIX levels greatly improved the fit of the model. Therefore, exclusion of such pre-
surgical FIX levels may lead to biased population PK parameter estimates. 
 
In the present study, age partially explained the inter-individual variability from CL and V1. In the final 
model, the best fit was obtained using a piecewise linear relation using two slopes with -0.89% and -
1.15% for ages below 34 years for body weight normalized CL and V1, respectively. Allometric scaling 
of CL using an exponential factor of 0.75 partly explains the increased clearance when a lower body 
weight is present. Nevertheless, additional variability was explained by taking age into account. 
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Björkman et al. reported a similarly piecewise linear relationship between age and CL of rFIX when 
administered in a non-surgical situation [28,29]. It was shown that clearance and (steady-state) 
volume of distribution decreased when age increased from 2 to 20 years. Above an age of 20 years, 
there was virtually no change in clearance or volume of distribution. Suzuki et al explored a similar 
piecewise relationship of age with CL for the population PK of rFIX as well [13]. However, a 
relationship between age and CL could not be identified when body weight was included in the model 
as well. Furthermore, in the covariate analysis, severity of hemophilia B was associated with V1. For a 
moderate hemophilia B patient, V1 was 10.5% lower as compared to a severely affected patient, 
which is in agreement with the findings from Ewenstein et al.[30] 
 
In previous studies, differences have been reported between PK parameters from pdFIX and rFIX 
products in the non-surgical situation [5,30,31]. The in vivo recovery for rFIX products was found to be 
on average 53% that of pdFIX products [5]. As in vivo recovery is inversely related to volume of 
distribution, V1 is lower for pdFIX products. Moreover, the clearance of rFIX products was found to be 
approximately twice as high as compared to pdFIX products [32]. In the presents study, CL and V1 of 
pdFIX were 11.2% and 17.3% lower than their respective values for rFIX. These higher values for CL 
and V1 from rFIX are in accordance with results from previous studies. However, the difference 
between the types of products is smaller in the surgical situation than in the non-surgical situation. 
 
In Figure S2, each published non-surgical population PK model showed that the observed 
perioperative FIX levels were underpredicted. These differences were also demonstrated by 
simulations of the typical FIX level versus time profiles for a patient receiving 100 IUkg
-1
 of pdFIX or 
rFIX using the available population PK models (Figure S5). The calculated rMPEs and half-lives 
clearly demonstrate that the PK of FIX in the non-surgical setting is different from the surgical setting. 
The extent of underprediction was higher for rFIX model 1 and 2 (-40.7% and -40.3%) compared to 
pdFIX model 1 and 2 (-7.2% and -15.7%). This may be explained by the fact that CL in the non-
surgical situation was almost twice as high as the value in the present study: 560 mLh
-1
70kg
-1 
and 551 
mLh
-1
70kg
-1 
versus 284 mLh
-1
70kg
-1
, respectively. For the pdFIX models, there was less 
underprediction. Values for CL in the non-surgical situation were slightly higher than the values from 
the present study: 290 mLh
-1
70kg
-1
 and 319.8 mLh
-1
70kg
-1
 versus 284 mLh
-1
70kg
-1
. An explanation for 
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this difference is unknown. Nevertheless, the currently published population PK models for 
prophylactic treatment with rFIX and pdFIX underpredict the perioperative FIX levels. Consequently, 
use of these models in the perioperative situation result in overdosing. 
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Conclusion 
In the present study, a population PK model was established that adequately described the 
perioperative FIX levels as obtained from hemophilia B patients undergoing a surgical procedure. As 
differences in the population PK were found between the surgical and non-surgical setting, the 
dedicated population PK model constructed in this study may be applied for patient-tailored dosing in 
the perioperative period. However, application of a population PK model for clinical use should always 
be validated. 
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Table S1. Model for body weight imputation using age 
Parameter Unit Estimate RSE (%) 
β1 – y-intercept kg 6.3 (7) 
β2 – coefficient for all ages kg year
-1
 3.6 (5) 
β3 – coefficient for age > β4 kg year
-1
 -3.73 (7) 
β4 – Inflection point year 23.5 (8) 
Residual variability    
Proportional error %CV
†
 19.1 (6) 
RSE indicates relative standard error; kg, kilogram. CV, coefficient of variation. By the estimated 
parameter, the following equation was obtained: WTest (kg) = 6.3 + 3.6*age - 3.73*(age - 23.5 )
DAGE
. In 
this equation, DAGE is 1 in the case that the age of the patient is 23.5 years or older, in every other 
case it is zero. 
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Table S1. Population PK parameter estimates from published models 
 pdFIX model 1  pdFIX model 2  rFIX model 1  rFIX model 2 
 
Estimate 
RSE 
(%) 
 
Estimate 
RSE 
(%) 
 Estimate RSE (%) 
 
Estimate RSE (%) 
Structural model            
Clearance (CL; mLh
-1
70kg
-1
) 290 3.7  319.8 7.2  560 3.1  551 2.2 
Volume of central compartment (V1; mL70kg
-1
) 5710 3.6  5922 7.0  6090 14  9770 4.0 
Distribution CL to compartment 2 (Q2; mLh
-1
70kg
-1
) 1990 35  1049 20.3  22400 28  577 12.6 
Volume of compartment 2 (V2; mL70kg
-1
) 810 19  828.9 50.7  4160 17  4620 4.1 
Distribution CL to compartment 3 (Q3; mLh
-1
70kg
-1
) 170 6.7  160.4 8.1  430 15  ND  
Volume of compartment 3 (V3; mL70kg
-1
) 2890 10  2234 73.9  3900 7.7  ND  
Baseline FIX level ND   0.01588 10.9  ND   ND  
Inter-individual variability (%CV)            
IIV on CL 23 64  36.8 36.8  19 18  25.6 18.9 
IIV on V1 19 37  41.2 34.2  46 36  23.2 10.2 
IIV on V2 63 30  97.4 72.6  28 44  37.5 13.7 
IIV on V3 78 81  133.2 34.5  19 71  ND  
IIV on Q2 ND   ND   ND   69.1 17.6 
Inter-occasion variability (%CV)            
IOV CL 15 36  48.8 10.1  ND   24.7 14.3 
IOV V1 12 24  47.2 17.8  ND   18.9 8.6 
Residual variability            
Additive residual variability (SD; IUmL
-1
) 0.0037 10  0.0067 3.1  0.0064 12  0.00614 8.4 
Proportional residual variability (%CV) 9.2 11  6.95 1.5  8.7 4.9  6.8 11.7 
RSE indicates relative standard error; mL, milliliter; h, hour; kg, kilogram; CV, coefficient of variation; SD, standard deviation; Allometric coefficients, covariate relations and correlations for IIV and IOV are not 
shown. pdFIX model 1
12
, pdFIX model 2
24
, rFIX model 1
11
, rFIX model 2
13
. 
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Table 1. General characteristics of the study population 
 
Total cohort 
 
Adults 
 
Children* 
No. (%) or median [range] 
Patient characteristics 
        
 
No. of patients 118   82   36  
 
Age (years) 40 [0.2-90]  46 [18-90]  6 [0.2-18] 
 
Body weight (kg) 79 [5.3-132]  85 [47-132]  19 [5.3-117] 
 Severe hemophilia B (<0.01 IUmL
-1
) 85 (72)  57 (70)  28 (78) 
 On prophylaxis 36 (31)  28 (34)  8 (22) 
 Blood group O
†
 33 (28)  24 (29)  9 (25) 
 Neutralizing antibodies (historically) 6 (5)  5 (6)  1 (3) 
 Chronic hepatitis C 47 (40)  46 (56)  1 (3) 
 Patient treated in the United Kingdom 93 (79)  63 (77)  30 (83) 
Surgical characteristics 
  
 
  
 
  
 
No. of surgical procedures 255   201   54  
  
Total no. of patients undergoing:         
  
1 118   82   36  
  
2 63   49   14  
  
3 32   28   4  
  
>3 42   42   0  
 Minor surgical procedures 135 (53)  96 (48)  39 (72) 
 Major surgical procedures 120 (47)  105 (52)  15 (28) 
Replacement therapy with FIX concentrate 
 Mode of infusion         
   Continuous 56 (22)  54 (27)  2 (4) 
   Bolus 199 (78)  147 (73)  52 (96) 
 Product type         
   Recombinant
 
201 (79)  150 (75)  51 (91) 
   Plasma-derived
 
54 (21)  51 (25)  3 (6) 
PK data 
 Total number of observations 1555   1324 (85%)  231 (15) 
 No. of observations per occasion 4 [1-23]  10 [1-23]  5 [1-16] 
 No. of doses per occasion 7 [1-52]  12 [1-52]  12 [1-39] 
No. indicates number; kg, kilogram; and IUmL
-1
, international units per milliliter. *Children were defined as having an age less than 18 years. 
†Blood group available in 80 patients. Adapted from Hazendonk et al
7
 with permission. 
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Table 2. Estimated population PK parameters for the structural model, final model, and bootstrap analysis 
 Structural model  Final model  Bootstrap analysis 
 
Estimate RSE (%) Shr. (%)  Estimate 95% CI Shr. (%)  Estimate 95% CI 
Structural model           
Clearance (CL; mLh
-1
70kg
-1
) 296 2.5   284 [266 - 302]   283 [265 - 300] 
Volume of central compartment (V1; mL70kg
-1
) 5370 2.7   5450 [5005 - 5895]   5426 [4933 - 5886] 
Distribution CL to compartment 2 (Q2; mLh
-1
70kg
-1
) 112 25   110 [86 - 134]   110 [92 - 140] 
Volume of compartment 2 (V2; mL70kg
-1
) 4720 16.7   4800 [3793 - 5807]   4879 [4118 - 6367] 
Distribution CL to compartment 3 (Q3; mLh
-1
70kg
-1
) 2210 19.9   1610 [-32 - 3252]   1943 [667 - 5132] 
Volume of compartment 3 (V3; mL70kg
-1
) 2160 17.7   2040 [1344 - 2736]   2079 [1376 - 2753] 
Virtual dose 0.998 22.0   ND    ND  
Inter-individual variability (%CV)           
IIV on CL 20.8 9.1 12.3  18.5 [16.4 – 21.3] 10.2  18.5 [15.3 – 21.5] 
IIV on V1 24.6 12.2 14.5  18.7 [16.5 – 21.4] 15.0  18.7 [14.0 – 23.5] 
Correlation between CL and V1 (%) 91.3 11.2   89.4 [85.0 – 92.5]   89.1 [88.6 – 91.6] 
IIV on virtual dose 94.5 18.0   ND    ND  
Inter-occasion variability (%CV)           
IOV on virtual dose 93.4 10.2   ND    ND  
Residual variability           
Proportional residual error (%CV) 23.0 4.2   21.9 [20.2 – 23.6]   21.7 [20.0 – 23.3] 
Covariate relations           
CL – (% change with age different from 34 years) -    -0.89 [-1.4 - -0.4]   -0.89 [-1.4 - -0.4] 
V1 – (% change with age different from 34 years) -    -1.15 [-1.7 - -0.6]   -1.14 [-1.7 - -0.6] 
CL – plasma-derived product (%) -    88.8 [83.8 - 93.8]   88.9 [84.3 - 94.6] 
V1 – plasma-derived product (%) -    82.7 [74.7 - 90.7]   82.3 [72.5 - 90.8] 
V1 – if moderate hemophilia patient (%) -    89.5 [82.8 - 96.2]   89.1 [82.3 - 96.3] 
Model characteristics           
Objective function value -2827.12    -2905.27    ND  
Condition number 68.65    119.65    ND  
RSE indicates relative standard error; CI, confidence interval as obtained using the 2.5
th
 and 97.5
th
 percentiles from the non-parametric distributions; mL, milliliter; h, hour; kg, 
kilogram; CV, coefficient of variation; Shr., shrinkage. The typical values are obtained for a severe haemophilia B patient weighing 70 kg receiving a recombinant factor IX product. 
!" !"ℎ
!!
= 284 ! 
!"
70
!.!"
! 1 − 0.0089 ! !"# − 34
!"#!!"
 ! 0.888
!"#$%#!!"#$%"! !"#$%&'
  
!1 !" = 5450 ! 
!"
70
!.!
! 1 − 0.0115 ! !"# − 34
!"#!!"
 ! 0.827
!"#$%#!!"#$%"! !"#$%&'
 ! 0.895
!"#$%&'$ !!"#$!!"!#  
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Table 3. Model building-steps 
 
 OFV dOFV 
No. of 
parameters 
Structural model    
1 Structural model with doses calculated using the virtual dose -2827.1 ND 9 
Covariate relationships – forward inclusion    
2 Structural model and age on CL -2832.7 -5.6 10 
3 Model 2 and age on V1 -2856.4 -23.6 11 
4 Model 3 and plasma-derived products on CL -2876.6 -20.3 12 
5 Model 4 and plasma-derived product on V1 -2897.6 -20.9 13 
6 Model 5 and moderate patient, as compared to severe patient on V1 -2905.3 -7.7 14 
Covariate relationships – backward deletion    
7 Model 6 without moderate patient, as compared to severe patient on V1 -2897.6 7.7 13 
8 Model 6 without age on CL -2881.4 23.9 13 
9 Model 6 without age on V1 -2883.2 22.1 13 
10 Model 6 without plasma-derived products on CL -2871.8 33.5 13 
11 Model 6 without plasma-derived products on V1 -2880.3 25.0 13 
OFV indicates objective function value, as calculated by minus two times the logarithm of the likelihood (-2LL) of the model describing the 
data; No., number; 
*
 For these models, the coefficients for covariate age on both CL and V1 were estimated using a piecewise linear model. 
However, the slope for the ages above 33.6 years was fixed to 0. Therefore, the number of parameters does only increase by 1. 
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Supplemental data 
 
Software 
Perioperative FIX dosing and coagulation factor IX (FIX) level measurement data were analyzed 
simultaneously for all patients using NONMEM version 7.4 (ICON Development Solutions, Ellicott City, 
MD, USA).[1] First-order conditional estimation with interaction was applied to obtain estimates for all 
model parameters. Perl-speaks-NONMEM version 4.7.0 was used to aid model development and 
Pirana served as a model management tool.[2] Data preparation and model diagnostics were 
performed using R version 3.4.1 (R Core Team, 2017) with Xpose version 4.6.0.[1,3,4] 
 
Structural model development 
In literature, the population PK of FIX is predominantly described by three-compartment models.[5–8] 
In our study, however, it was uncertain whether the data would allow estimating all parameters from a 
three-compartment model with adequate precision, which depends on the timing of sampling. 
Therefore, development of the model was initiated by fitting a two-compartment model to the data. 
Subsequently, it was evaluated if the addition of a third compartment would improve the fit. The 
observed FIX levels and the model predicted FIX levels were both transformed by calculating the 
natural logarithm.[9] 
PK parameters estimates for a two-compartment model were clearance from the central compartment 
(CL), inter-compartmental clearance (Q2), the volume of the central compartment (V1) and second 
peripheral compartment (V2). For a three-compartment model, the inter-compartmental clearance 
between the central and third peripheral compartment (Q3) and the volume of the third peripheral 
compartment (V3) were added. 
Different residual error models were evaluated, including an additive, proportional and combined 
(additive and proportional) error model[10], as shown by the following equations respectively: 
(1) !!" =  Ĉ!"  ∙ 1 + !!"! + !!"! 
in which Cij is the measured FIX level for the i
th
 observations from the j
th
 individual, Ĉij is the predicted 
FIX level, εij1 is the proportional residual error and εij2 is the additive residual error. In case a 
proportional or combined error model was applied to the model, interaction between the residual 
variability and IIV was allowed. 
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First, a structural model was developed, in which typical values for the PK parameters were estimated 
in combination with their inter-patient variability (IIV). Because patients could have undergone more 
than one surgical procedure, inter-occasion (between-surgery) variability (IOV) of the population PK 
parameters was also estimated. An exponential model was used to estimate IIV and IOV, as described 
by the following equation: 
(2) !!" =  !!"  ! !"#
!!!!!" 
in this expression, the subscripts i and k denote the number of the individual and the occasion, 
respectively, θTV is the estimated typical value for a population PK parameter, θik is the estimated 
individual PK parameter, and η and κ are the random-effects accounting for IIV and IOV, respectively. 
In some cases, preoperative FIX levels were increased due to a prior FIX dose of which timing was 
unknown. In these cases, this dose was estimated by a preoperative virtual dose of 8250 IU given 5 
days prior to the pre-dose FIX measurement. The bioavailability of the virtual dose was estimated with 
IIV and IOV, as described by equation 2, allowing the dose to adjust to the dose necessary to describe 
the preoperative FIX level. 
For all other dosing and FIX level measurement data, the bioavailability is set to one. This allows 
describing the PK from the time of administration of the virtual dose by all PK parameters, instead of 
using only the terminal elimination half-life to correct for pre-dose FIX measurements.[11] 
Since FIX PK data were available for both children and adults, PK parameters were allometrically 
normalized to a body weight of 70 kg. Scaling was performed a priori; i.e. no evaluation of scaling 
performance was conducted by the following equation: 
(3) !!" =  !!  ! 
!"
!"
!!
 
in which θi is a population PK parameter, θTV is the typical value for this parameter, BW is body weight 
and θp is the allometric exponent. Allometric exponents were fixed to 1 in case of a volume parameter 
(V1, V2, V3) and to 0.75 for all clearance parameters (CL, Q2, Q3).[12] 
For every patient, age was known at the time of each surgical procedure. However, body weight was 
missing in 40 surgical procedures (16%). Therefore, a linear model in NONMEM was developed to 
impute the missing values for body weight using age as a predictor. A piecewise linear model was 
selected by graphical exploration. The following equation was used to estimate body weight using the 
values for age: 
(4) !!" =  !! + !!!"#$ + !!! !"# −  !!  ! !!  
!"# ≤  !!: !! = 0
!"# >  !!: !! = 1
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in which θBW is the imputed body weight, β1 is the y-intercept, β2 the slope of the predictor age for all 
ages, β3 the slope for the predictor age higher than the value for the inflection point using β4. Since β3 
only describes body weight higher than this inflection point, β5 is 0 below this age and 1 in other cases. 
 
Covariate analysis 
After the structural model was established, patient demographics and pathophysiological and surgical-
characteristics, which can explain the inter-individual variability or the residual variability, were 
evaluated. First, a univariate analysis was performed to obtain a pre-selection of eligible covariate 
relationship. Hereby, a significant decrease in OFV (associated with a P < .05) determines if the 
covariate relation is eligible to be included in the covariate model. Subsequently, a multivariate 
analysis was conducted to test whether the eligible relationships would also significantly decrease the 
OFV when included simultaneously. Consecutively, a backward elimination procedure was performed, 
in which the included relations are discarded one by one from the final covariate model. In this 
procedure, relations are retained in the covariate model if the increment in OFV is associated with a P 
> .01. 
All covariate-relationships were evaluated by means of univariate analyses and graphical evaluations 
to explain the inter-individual variability or the residual variability. The following covariates were 
evaluated by a dichotomous relationship: the distinction between severe or moderate hemophilia, the 
use of tranexamic acid or heparin during surgery, administration of recombinant (r) or plasma-derived 
(pd) FIX, country of treatment, having hepatitis C, the use of prophylaxis before the surgical 
procedure, a history of neutralizing inhibitors, having a minor or major surgical procedure, having 
blood group O, having an infection or a decrease in hemoglobin concentration during the surgical 
procedure, and the brand of product. For all dichotomous covariate relationships, the following 
equation were used: 
(5) !! = !!" ∗ !!"# 
and in case the covariate values was missing: 
(6) !! = !!" ∗ !!"#_!"##"$% 
in which θcov and θcov_missing are the fraction of the typical PK parameter θTV. For example, an estimate 
for θcov was obtained in case a patient used pdFIX during the surgical procedure or if a patient was 
diagnosed with moderate hemophilia. In other cases, i.e. when a rFIX product was administered or the 
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patient was diagnosed with severe hemophilia, the value of θcov was 1, meaning that θTV was not 
altered. Thereby, estimated values for θTV describe the case when θcov is set to 1. For the dichotomous 
relationships, the missing values were regarded as being missing at random and, therefore, regarded 
as a separate group with a fraction value of θcov_missing. To describe the relationship of age, the 
following linear model was applied: 
(7) !! = !!" ∗ 1 + !!" ∗ !"# − !"#!"#  
in which θi describes the individual PK parameter, θTV is the typical (median) value for a population PK 
parameter and θSL is the slope of the relation of age. This model could be used as a piecewise linear 
model by allowing θSL to be different, based on a cut-off point for age. For instance, the median age 
could be used for this cut-off point between the two slopes and, thereby, describing a piecewise linear 
model. 
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